Tech Logic

Columbia University team publishes study in Science: key protein synthesis mechanism in E. coli reprogrammed to use only 19 amino acids

Based on cross-checking three sources, a Columbia University team led by Harris Wang published a study in Science that redesigns a key protein-synthesis mechanism in E. coli so its core process uses only 19 amino acids. All three sources confirm the research topic, main organism, and publication venue; on the specific technical path, Source 2 mentions an early test in which isoleucine in 36 essential genes was replaced with valine. Further experimental details, motivation, and full results cannot be confirmed from the provided sources.

May 6, 2026

York Space Systems to Acquire ALL.SPACE for About $355 Million in Cash-and-Stock Deal

York Space Systems plans to acquire satellite terminal maker ALL.SPACE (All.Space Holdings) for about $355 million, according to SEC filings. Three sources confirm the deal’s total value and the payment structure: $155 million in cash plus up to 5.9 million York shares. If approved, ALL.SPACE will become York’s wholly owned subsidiary. Sources also note that York is extending into satellite communications terminals, user equipment, and network connectivity, though the specific strategic rationale and integration details were not confirmed by all sources.

May 5, 2026

Commonwealth Fusion Systems Enters PJM Interconnection Queue for the First Time, Aiming to Connect a 400MW Fusion Power Plant to the U.S. Grid

Commonwealth Fusion Systems has submitted an interconnection request to PJM Interconnection with the goal of connecting its planned first commercial fusion power plant to the U.S. grid. Three sources consistently confirm that the project is located in Virginia, has a planned capacity of 400MW, and is targeting power delivery in the early 2030s. However, differences remain across the sources regarding the project’s name, the timing of the application, and the details of its commercialization progress.

May 2, 2026

Intellia’s in vivo CRISPR therapy lonvo-z meets Phase 3 HAELO endpoints, rolling BLA filing begins

Intellia Therapeutics disclosed on April 27, 2026, that its in vivo CRISPR gene-editing therapy lonvo-z, formerly NTLA-2002, met the primary endpoint and all key secondary endpoints in the Phase 3 HAELO trial for hereditary angioedema (HAE), and has begun a rolling BLA submission to the U.S. FDA. Three sources consistently point to positive Phase 3 results and view the program as a milestone for the in vivo CRISPR field, with only minor differences in trial details and emphasis.

Apr 30, 2026

NASA's Commercial LEO Space Station Procurement Strategy Draws Debate as Companies Seek Market Validation at Space Symposium

After NASA signaled new views on market demand and procurement strategy for commercial low-Earth orbit stations (CLD), companies including Axiom Space and Voyager Technologies responded and sought market validation at the 41st Space Symposium in Colorado Springs. Cross-source reporting confirms the central dispute is whether a commercial space station market has reached sufficient demand, and whether customer demand beyond NASA is large enough to support the program. However, the provided sources do not offer fully consistent information on specific demand figures, NASA's latest strategy details, or the complete positions of all parties.

Apr 21, 2026